May 5, 2020 @ 7:30 pm
De Grandpré Communications Center, the Neuro
3801 University St.
Free for members of the SJLS, $12 for non-members
The Montreal Neurological Institute (The Neuro) is a world-leading brain research institute and hospital and part of both McGill University and the McGill University Health Centre. The Neuro is a place where clinicians and scientists from different disciplines work side-by-side, creating a seamless continuum from the lab bench to the patient’s bedside and back again.
The Neuro is now transforming itself into a unique “open science” institution in order to accelerate the pace of discovery of new cures and more effective treatments for patients affected by neurological diseases.
Join us for a panel discussion to learn more about how open science will help tackle the most urgent brain disease challenges and serve patient communities in dire need of therapeutic solutions like those living with ALS, Parkinson’s, brain tumours, autism and other rare neurological diseases.
DR. EDWARD FON
is a clinician-scientist specializing in Parkinson’s disease and movement disorders. He is the Director of the McGill National Parkinson Foundation Centre of Excellence and of the FRQS Quebec Parkinson Network. Dr. Fon is the Scientific Director of The Neuro and Director of the Drug Discovery Platform. The Platform works with human induced stem cells (iPSCs) to understand the molecular basis of disease and identify potential treatments.
DR. ALAN EVANS is the co-director of the Ludmer Centre for Neuroinformatics and Mental Health and researcher in the McConnell Brain Imaging Centre – a one-of-a-kind research centre and multimodal platform entirely dedicated to neuroimaging. Dr. Evans is a world-renowned authority on brain mapping through the use of imaging technologies. His work focuses on both the developing brain and disorders like autism, and the aging brain and diseases like Alzheimer’s and dementias. He will also discuss the recent acquisition of a multi-million dollar 7 Tesla imaging machine.
DR. ANGELA GENGE is the Director of the Clinical Research Unit. The CRU conducts clinical trials in order to evaluate the efficacy of new drugs and treatment regimens. Dr. Genge, in addition to being an attending neurologist at The Neuro, is an active clinical investigator involved with numerous trials and work groups. Dr. Genge has worked tirelessly to expand both the number and scope of clinical trials in neurological disease including Multiple Sclerosis, ALS, epilepsy, migraines, pain, brain tumour, and stroke.